drugset
drugset / Trial / NCT07678593

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

NCT07678593 ↗

Phase 1/2 Not yet recruiting 222 enrolled Genfleet Therapeutics (Shanghai) Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Timeline

Start
2026-09
Primary completion
2027-11
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Subject GFH276 Unknown — Oral
Background Cetuximab Monoclonal antibody 500 mg/m2 Intravenous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Irinotecan Small molecule 150 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background Paclitaxel Small molecule 125 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

pancreatic ductal adenocarcinoma